marimastat has been researched along with Neoplasms in 27 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (37.04) | 18.2507 |
2000's | 15 (55.56) | 29.6817 |
2010's | 1 (3.70) | 24.3611 |
2020's | 1 (3.70) | 2.80 |
Authors | Studies |
---|---|
DasGupta, S; Giridhar, R; Murumkar, PR; Yadav, MR | 1 |
Anceschi, C; Chiarugi, P; Chillà, A; De Palma, G; Del Rosso, M; Del Rosso, T; Fibbi, G; Frediani, E; Laurenzana, A; Margheri, F; Pelagio, G; Scavone, F; Tufaro, A | 1 |
Cho, SH; Duin, EC; Hong, JW; Jambovane, S; Kim, SK; Yun, JY | 1 |
Augustin, HG | 1 |
Goodin, S; Gounder, M; Lin, Y; Medina, M; Much, J; Musanti, R; Orlando, T; Pennick, M; Rubin, E; Shih, W; Toppmeyer, DL; Vyas, V | 1 |
Muehlbauer, PM | 1 |
Peterson, JT | 1 |
Balkwill, F; Blann, AD; Caine, GJ; Christodoulos, K; Dobbs, N; Ganesan, TS; Gompertz, N; Harris, AL; Jones, PH; Kakkar, AJ; Kumar, S; Talbot, DC; Thavasu, P | 1 |
Didziapetriene, J; Kadziauskas, J; Stanciūte, D | 1 |
Blann, AD; Caine, GJ; Christodoulos, K; Harris, AL; Lip, GY | 1 |
Kuwano, M; Ono, M | 2 |
Dickson, RB; Hawkins, MJ; Wojtowicz-Praga, SM | 1 |
Brown, PD | 1 |
Denis, LJ; Verweij, J | 1 |
Berrington, A; Brown, P; Cornish, A; Cox, D; Kerr, D; Lynch, K; Malfetano, J; Millar, A; Nemunaitis, J; Poole, C; Primrose, J; Rasmussen, H; Rosemurgy, A | 1 |
Davidson, S | 1 |
Steward, WP | 1 |
Bout, JC; Soncin, F; Vandenbunder, B | 1 |
Fingleton, B; Matrisian, LM; Nelson, AR; Rothenberg, ML | 1 |
Sone, S | 1 |
Sasaki, Y; Tahara, M | 1 |
Steward, WP; Thomas, AL | 1 |
Eckhardt, SG; Hidalgo, M | 1 |
Shiraga, M; Sone, S | 1 |
Bergen, M; Eckhardt, SG; Hidalgo, M; Holden, SN; Pierson, AS | 1 |
17 review(s) available for marimastat and Neoplasms
Article | Year |
---|---|
Current perspective of TACE inhibitors: a review.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Arthritis, Rheumatoid; Enzyme Inhibitors; Humans; Models, Molecular; Neoplasms; Structure-Activity Relationship | 2009 |
[Angiogenesis research--quo vadis?].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Cell Communication; Drug Evaluation, Preclinical; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Ephrins; Forecasting; Growth Substances; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Lymphokines; Metalloendopeptidases; Mice; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Phenylalanine; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Research; Signal Transduction; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Anti-angiogenesis in cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Clinical Trials as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Lymphokines; Neoplasms; Oncology Nursing; Thalidomide; Tissue Extracts; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.
Topics: Cardiomyopathy, Dilated; Collagen; Doxycycline; Drug Design; Enzyme Activation; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Musculoskeletal Diseases; Myocardium; Neoplasms; Periodontal Diseases | 2004 |
[Expression of matrix metalloproteinases in patients with malignant tumors].
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Clinical Trials as Topic; Diphosphonates; Disease Progression; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Prognosis; Protease Inhibitors; Thiophenes; Time Factors; Tissue Inhibitor of Metalloproteinases | 2004 |
[Development of anti tumor agents targeting angiogenesis].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-12; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Platelet Factor 4; Polysaccharides, Bacterial; Sesquiterpenes; Thalidomide; Thiophenes; Triazines; Triazoles; Tumor Cells, Cultured | 1997 |
Matrix metalloproteinase inhibitors.
Topics: Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Down-Regulation; Drugs, Investigational; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hydroxamic Acids; Metalloendopeptidases; Molecular Weight; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Phenylalanine; Protease Inhibitors; Protein Kinase C; Proteins; Thiophenes; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-3; Tissue Inhibitor of Metalloproteinases | 1997 |
Matrix metalloproteinase inhibitors in the treatment of cancer.
Topics: Clinical Trials as Topic; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasms | 1997 |
Matrix metalloproteinase inhibitors: present achievements and future prospects.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasm Metastasis; Neoplasms; Phenylalanine; Protease Inhibitors; Thiophenes | 1997 |
[Neovascularization and tumor development].
Topics: Angiostatins; Antibiotics, Antineoplastic; Antineoplastic Agents; Collagen; Cyclohexanes; Endostatins; Humans; Hydroxamic Acids; Interferons; Interleukin-12; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Peptide Fragments; Phenylalanine; Plasminogen; Sesquiterpenes; Thalidomide; Thiophenes | 1998 |
Marimastat (BB2516): current status of development.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasms | 1999 |
[Clinical development of new molecular targeted therapeutics for cancer therapy].
Topics: Angiogenesis Inhibitors; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Hydroxamic Acids; Neoplasms | 2000 |
[Dose escalation strategies of molecular target drugs].
Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasms | 2000 |
Marimastat: the clinical development of a matrix metalloproteinase inhibitor.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Neoplasms | 2000 |
Development of matrix metalloproteinase inhibitors in cancer therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Protease Inhibitors; Pyrazines; Sulfonamides; Tetracycline; Tetracyclines; Thiophenes | 2001 |
[Matrix metalloproteinase inhibitors for therapy of cancer].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; Treatment Outcome | 2001 |
Therapeutic angiogenesis inhibitors in the treatment of cancer.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Collagen; Endostatins; Endothelial Growth Factors; Enzyme Inhibitors; Estradiol; Humans; Hydroxamic Acids; Lymphokines; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals; Peptide Fragments; Protein-Tyrosine Kinases; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
3 trial(s) available for marimastat and Neoplasms
Article | Year |
---|---|
A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Molecular Structure; Neoplasms; Paclitaxel | 2003 |
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Captopril; Dalteparin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fibrinolytic Agents; Humans; Hydroxamic Acids; Injections, Subcutaneous; Lymphocytes; Male; Middle Aged; Neoplasms; Phytohemagglutinins; Treatment Outcome; Tumor Necrosis Factor-alpha | 2004 |
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Biomarkers, Tumor; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Male; Metalloendopeptidases; Middle Aged; Neoplasm Staging; Neoplasms; Survival Rate | 1998 |
7 other study(ies) available for marimastat and Neoplasms
Article | Year |
---|---|
Inhibition of MMPs supports amoeboid angiogenesis hampering VEGF-targeted therapies via MLC and ERK 1/2 signaling.
Topics: Amoeba; Angiogenesis Inhibitors; Animals; Endothelial Cells; Female; MAP Kinase Signaling System; Matrix Metalloproteinases; Mice; Morphogenesis; Neoplasms; Neovascularization, Pathologic; Signal Transduction; Vascular Endothelial Growth Factor A | 2023 |
Log-scale dose response of inhibitors on a chip.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Kinetics; Lab-On-A-Chip Devices; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Microchip Analytical Procedures; Neoplasms; Phenylalanine; Sensitivity and Specificity; Spectrometry, Fluorescence; Thiophenes | 2011 |
Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anticoagulants; Captopril; Dalteparin; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; P-Selectin; Platelet Activation; Thromboplastin; Vascular Endothelial Growth Factor A | 2005 |
Is British Biotech's Marimastat a major cancer drug?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Enzyme Inhibitors; Humans; Hydroxamic Acids; Investments; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasms; United Kingdom | 1996 |
Marimastat. BB 2516, TA 2516.
Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Drugs, Investigational; Female; Humans; Hydroxamic Acids; Male; Melanoma; Metalloendopeptidases; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Stomach Neoplasms | 1999 |
[Therapeutic prospects of angiogenesis inhibitors in cancerology].
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Collagen; Endostatins; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinase Inhibitors; Mice; Neoplasms; Neoplasms, Experimental; Neovascularization, Pathologic; Peptide Fragments; Plasminogen; Protease Inhibitors; Randomized Controlled Trials as Topic | 1999 |
Matrix metalloproteinases: biologic activity and clinical implications.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Humans; Hydroxamic Acids; Matrix Metalloproteinase 1; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals | 2000 |